Allspring Global Investments Holdings LLC Acquires 10,644 Shares of Ascendis Pharma A/S $ASND

Allspring Global Investments Holdings LLC boosted its holdings in Ascendis Pharma A/S (NASDAQ:ASND) by 5.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 200,257 shares of the biotechnology company’s stock after acquiring an additional 10,644 shares during the quarter. Allspring Global Investments Holdings LLC owned 0.33% of Ascendis Pharma A/S worth $34,444,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in ASND. Compagnie Lombard Odier SCmA bought a new stake in Ascendis Pharma A/S in the second quarter valued at about $39,000. Brooklyn Investment Group increased its holdings in shares of Ascendis Pharma A/S by 332.9% during the first quarter. Brooklyn Investment Group now owns 355 shares of the biotechnology company’s stock worth $55,000 after buying an additional 273 shares in the last quarter. LVW Advisors LLC acquired a new stake in shares of Ascendis Pharma A/S during the second quarter worth approximately $202,000. Dearborn Partners LLC acquired a new stake in shares of Ascendis Pharma A/S during the first quarter worth approximately $203,000. Finally, New Wave Wealth Advisors LLC acquired a new stake in shares of Ascendis Pharma A/S during the first quarter worth approximately $222,000.

Analysts Set New Price Targets

Several analysts have recently weighed in on ASND shares. Royal Bank Of Canada raised their price objective on shares of Ascendis Pharma A/S from $210.00 to $230.00 and gave the stock an “outperform” rating in a report on Friday, August 8th. Wall Street Zen lowered Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research note on Friday, September 5th. JPMorgan Chase & Co. boosted their price objective on Ascendis Pharma A/S from $260.00 to $264.00 and gave the stock an “overweight” rating in a research note on Thursday, October 9th. UBS Group reissued a “buy” rating and issued a $307.00 price objective (up previously from $306.00) on shares of Ascendis Pharma A/S in a research note on Friday, August 8th. Finally, Cowen reissued a “buy” rating on shares of Ascendis Pharma A/S in a research note on Friday, August 8th. Fifteen analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Ascendis Pharma A/S currently has an average rating of “Moderate Buy” and an average target price of $248.29.

Ascendis Pharma A/S Price Performance

ASND opened at $207.12 on Thursday. Ascendis Pharma A/S has a one year low of $118.03 and a one year high of $216.45. The company’s 50 day simple moving average is $198.44 and its 200-day simple moving average is $176.71. The stock has a market capitalization of $12.78 billion, a P/E ratio of -40.14 and a beta of 0.41.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) EPS for the quarter, beating the consensus estimate of ($1.42) by $0.49. The company had revenue of $216.28 million for the quarter, compared to the consensus estimate of $163.17 million. As a group, analysts anticipate that Ascendis Pharma A/S will post -4.34 EPS for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.